Short Interest in Liminatus Pharma Inc. (NASDAQ:LIMN) Decreases By 45.5%

Liminatus Pharma Inc. (NASDAQ:LIMN) saw a large drop in short interest during the month of April. As of April 30th, there was short interest totaling 1,083,465 shares, a drop of 45.5% from the April 15th total of 1,989,468 shares. Currently, 2.4% of the company’s shares are sold short. Based on an average daily volume of 2,651,998 shares, the days-to-cover ratio is currently 0.4 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Liminatus Pharma in a report on Friday, March 27th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Liminatus Pharma Trading Down 2.2%

LIMN stock traded down $0.00 during trading on Friday, reaching $0.18. The stock had a trading volume of 754,434 shares, compared to its average volume of 1,005,395. Liminatus Pharma has a 1-year low of $0.16 and a 1-year high of $33.66. The company has a market capitalization of $8.08 million and a P/E ratio of -1.20. The firm has a fifty day moving average price of $0.20 and a 200 day moving average price of $0.61.

Liminatus Pharma (NASDAQ:LIMN) last released its earnings results on Friday, May 15th. The company reported ($0.03) earnings per share for the quarter.

Liminatus Pharma Company Profile

Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.